Charles River Laboratories | CRL - Current Assets


Charles River Laboratories reported $1.49B in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Agilent USD 4.76B 148M Mar/2026
Align Technology USD 2.66B 38.87M Mar/2026
Bio-Rad Laboratories USD 2.94B 35.9M Mar/2026
Bruker USD 2.1B 108.9M Mar/2026
Cardinal Health USD 38.06B 1.17B Mar/2026
Charles River Laboratories USD 1.49B 41.76M Mar/2026
Cigna USD 43.03B 4.78B Mar/2026
Concord Medical Services Hldg CNY 1.03B 174.49M Jun/2025
CVS Health USD 74.82B 103M Mar/2026
Danaher USD 13.94B 1.18B Mar/2026
Dentsply International USD 1.85B 178M Mar/2026
Elevance Health USD 67.03B 4.03B Mar/2026
Humana USD 38.08B 5.35B Mar/2026
Illumina USD 2.74B 551M Mar/2026
Incyte USD 5.48B 460.36M Mar/2026
Intrexon USD 23.72M 45.04M Jun/2024
IQVIA Holdings USD 6.22B 29M Mar/2026
Laboratory Of America USD 4.56B 538.3M Mar/2026
Lakefront Biotherapeutics EUR 3.06B 18.72M Mar/2026
Lonza CHF 8B 3.41B Dec/2025
McKesson USD 57.21B 2.49B Mar/2026
Merck EUR 14.16B 932M Mar/2026
Mettler Toledo International USD 1.33B 30.76M Mar/2026
Novartis USD 26.61B 3.85B Mar/2026
Pfizer USD 42.82B 76M Mar/2026
Quest Diagnostics USD 2.57B 188M Mar/2026
Revvity USD 2.13B 111.43M Mar/2026
Thermo Fisher Scientific USD 22.32B 6.39B Mar/2026
United Therapeutics USD 2.87B 830.5M Mar/2026
UnitedHealth USD 91.13B 545M Mar/2026
Veradigm USD 679.65M 131.12M Dec/2022
Waters USD 3.72B 1.73B Mar/2026
West Pharmaceutical Services USD 1.83B 151.4M Mar/2026